Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
about
Checkpoint Inhibitors and Their Application in Breast CancerDendritic cell-based cancer immunotherapy for colorectal cancerPapilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice.The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.Role of IL-2 in cancer immunotherapyChimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelT-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.Approaches for targeting cancer stem cells drug resistance.Cancer immunotherapy: weak beats strong.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma.Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases.Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression.Altered T-Cell Balance in Lymphoid Organs of a Mouse Model of Colorectal Cancer.Cancer Vaccines in Ovarian Cancer: How Can We Improve?Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
P2860
Q26745442-EB8DA119-B6D9-4593-B48D-A63506BD2CD7Q26751339-CCF4E565-BA73-436E-9E22-671749900E69Q33571959-B7CE6C0F-CF47-4437-9662-1781802A27EDQ36544576-AD1F2AAE-303C-4ADB-B237-33491E0500DDQ37079072-5FC47509-649E-4783-8EBD-DCB6743712EAQ37376269-98B427A2-114A-4132-A306-CD59AC4FB35FQ37662081-3A2332A7-5F42-4E90-B535-6D30E9FC87EDQ37684668-E8C9FEC1-0A7F-4D75-8D89-61D0356EFB1DQ38749945-B8B1DEDE-FAE2-4736-A51E-369332774E98Q38971795-C90FCE2C-0205-4371-B291-86169EABFE75Q40027037-AC7917B8-E4B7-4C23-8074-509BDB51654DQ42378527-BAAE8B8F-C2E0-4296-A36B-77DBD7D0ABFAQ45325729-5F6A4118-38E5-4375-9816-C4A574E4950AQ47097238-FC344EA1-82D3-45D8-BAC4-BB44EF4ECC1FQ47139741-91676518-FC8D-4EE3-97AE-9D7E21BDADC9Q48193685-CCDA2361-254F-476B-AAF0-3DA975D23AC1Q49838785-9D194C94-B207-4066-A6F9-E78999FB0A35Q50556905-84621165-482A-4998-964E-73F5F4BEA401Q54385315-90F20018-89D0-49BD-A8D2-839E22397BCCQ55447998-4820FF42-F982-4634-84A4-157DB2DDAE92
P2860
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@ast
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@en
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@nl
type
label
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@ast
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@en
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@nl
prefLabel
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@ast
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@en
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@nl
P2860
P3181
P356
P1433
P1476
Immune checkpoint blockade ope ...... ith a potent clinical efficacy
@en
P2093
Keishi Adachi
Koji Tamada
P2860
P304
P3181
P356
10.1111/CAS.12695
P407
P5008
P577
2015-08-01T00:00:00Z